NEW YORK, Nov 3 (Reuters) - Dendreon Corp (DNDN.O) on Wednesday reported a wider third quarter loss on costs associated with the launch of its new Provenge vaccine for advanced prostate cancer, but the company provided an encouraging forecast for future sales.
